The role of PET for interim response assessment in patients with Hodgkin's lymphoma

被引:0
作者
Zaucha, Jan [1 ]
Danielewicz, Iwona [2 ]
Malkowski, Bogdan [3 ]
Zaucha, Renata [4 ]
Lesniewski-Kmak, Krzysztof [2 ]
机构
[1] Gdanski Uniwersytet Med, Zaklad Propedeutyki Onkol, PL-81519 Gdynia, Poland
[2] Szpital Morski Gdyni, Gdynskie Ctr Onkol, Oddzial Chemioterapii, Gdyni, Poland
[3] Ctr Onkol Prof F Lukaszczyka Bydgoszczy, Zaklad Med Nuklearnej, Nuklearnej, Poland
[4] Gdanski Uniwersytet Med, Klin Onkol & Radioterapii, PL-81519 Gdynia, Poland
来源
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY | 2009年 / 13卷 / 04期
关键词
Hodgkin's lymphoma; positron emission tomography; POSITRON-EMISSION-TOMOGRAPHY; FDG-PET; PROGNOSTIC VALUE; AGGRESSIVE LYMPHOMA; PROGRESSION-FREE; CELL LYMPHOMA; CYCLES; CHEMOTHERAPY; DISEASE; BEACOPP;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
F-18 2-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) assessment after completion of therapy for lymphomas has been recently incorporated into the clinical guidelines and is also advocated in Poland by the National Health Fund. There is emerging evidence that in patients with Hodgkin's lymphoma (HL) PET performed early during chemotherapy predicts the therapy response better than post-therapy PET However, it is not clear which criteria should be adopted for an interim PET assessment because of minimal residual uptake (MRU), which hampers interpretation of PET scans as positive or negative. This brief review summarizes the evidence to date for the use of interim PET assessment in patients with advanced HL both using ABVD and BEACOPPesc chemotherapy. The rationale for performing an observational study in Poland aiming at defining criteria used for interim PET assessment which could be utilized in the future as a basis for early therapeutic modification in routine clinical practice is also discussed.
引用
收藏
页码:161 / 166
页数:6
相关论文
共 30 条
[1]   CHEMOTHERAPY FOR DIFFUSE LARGE-CELL LYMPHOMA - RAPIDLY RESPONDING PATIENTS HAVE MORE DURABLE REMISSIONS [J].
ARMITAGE, JO ;
WEISENBURGER, DD ;
HUTCHINS, M ;
MORAVEC, DF ;
DOWLING, M ;
SORENSEN, S ;
MAILLIARD, J ;
OKERBLOOM, J ;
JOHNSON, PS ;
HOWE, D ;
BASCOM, GK ;
CASEY, J ;
LINDER, J ;
PURTILO, DT .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (02) :160-164
[2]   Early restaging positron emission tomography with 18 F-fluorodeoxyglucose in aggressive non-Hodgkin's lymphomas: is it too easy to be true? [J].
Balzarotti, M ;
Magagnoli, M ;
Santoro, A .
ANNALS OF ONCOLOGY, 2003, 14 (07) :1155-1156
[3]   Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: A report from the German Hodgkin's lymphoma study group [J].
Behringer, K ;
Breuer, K ;
Reineke, T ;
May, M ;
Nogova, L ;
Klimm, B ;
Schmitz, T ;
Wildt, L ;
Diehl, V ;
Engert, A .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) :7555-7564
[4]  
BRUSAMOLINO E, 2009, HAEMATOLOGICA, V94, P505
[5]   Early response to chemotherapy:: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity? [J].
Carde, P ;
Koscielny, S ;
Franklin, J ;
Axdorph, U ;
Raemaekers, J ;
Diehl, V ;
Aleman, B ;
Brosteanu, O ;
Hasenclever, D ;
Oberlin, O ;
Bonvin, N ;
Björkholm, M .
ANNALS OF ONCOLOGY, 2002, 13 :86-91
[6]   The Case Against Heavy PETing [J].
Cheson, Bruce .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (11) :1742-1743
[7]   Revised response criteria for malignant lymphoma [J].
Cheson, Bruce D. ;
Pfistner, Beate ;
Juweid, Malik E. ;
Gascoyne, Randy D. ;
Specht, Lena ;
Horning, Sandra J. ;
Coiffier, Bertrand ;
Fisher, Richard I. ;
Hagenbeek, Anton ;
Zucca, Emanuele ;
Rosen, Steven T. ;
Stroobants, Sigrid ;
Lister, T. Andrew ;
Hoppe, Richard T. ;
Dreyling, Martin ;
Tobinai, Kensei ;
Vose, Julie M. ;
Connors, Joseph M. ;
Federico, Massimo ;
Diehl, Volker .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586
[8]   Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome [J].
Dann, Eldad J. ;
Bar-Shalom, Rachel ;
Tamir, Ada ;
Haim, Nissim ;
Ben-Shachar, Menachem ;
Avivi, Irit ;
Zuckerman, Tzila ;
Kirschbaum, Mark ;
Goor, Odelia ;
Libster, Diana ;
Rowe, Jacob M. ;
Epelbaum, Ron .
BLOOD, 2007, 109 (03) :905-909
[9]   Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease [J].
Diehl, V ;
Franklin, J ;
Pfreundschuh, M ;
Lathan, B ;
Paulus, U ;
Hasenclever, D ;
Tesch, H ;
Herrmann, R ;
Dörken, B ;
Müller-Hermelink, H ;
Dühmke, E ;
Loeffler, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (24) :2386-2395
[10]   ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial [J].
Federico, Massimo ;
Luminari, Stefano ;
Iannitto, Emilio ;
Polimeno, Giuseppe ;
Marcheselli, Luigi ;
Montanini, Antonella ;
La Sala, Antonio ;
Merli, Francesco ;
Stelitano, Caterina ;
Pozzi, Samantha ;
Scalone, Renato ;
Di Renzo, Nicola ;
Musto, Pellegrino ;
Baldini, Luca ;
Cervetti, Giulia ;
Angrilli, Francesco ;
Mazza, Patrizio ;
Brugiatelli, Maura ;
Gobbi, Paolo G. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :805-811